Survival analysis according to time-varying MRD positivity (time points)
| . | TTP risk for MRD positivity by RQ-PCR in BM at different time points . | ||
|---|---|---|---|
| . | TTP . | ||
| RQ-PCR POS in BM (subjects) . | HR . | 95% CI . | P value . |
| R-CTX (#167) | 1.50 | (0.94-2.37) | .086 |
| R-HD-ARAC (#141) | 1.50 | (0.86-2.62) | .2 |
| Post-ASCT (#138) | 1.81 | (1.02-3.20) | .043 |
| M6 (#99) | 3.82 | (1.92-7.62) | <.001 |
| M12 (#90) | 5.60 | (2.68-11.7) | <.001 |
| . | TTP risk for MRD positivity by RQ-PCR in BM at different time points . | ||
|---|---|---|---|
| . | TTP . | ||
| RQ-PCR POS in BM (subjects) . | HR . | 95% CI . | P value . |
| R-CTX (#167) | 1.50 | (0.94-2.37) | .086 |
| R-HD-ARAC (#141) | 1.50 | (0.86-2.62) | .2 |
| Post-ASCT (#138) | 1.81 | (1.02-3.20) | .043 |
| M6 (#99) | 3.82 | (1.92-7.62) | <.001 |
| M12 (#90) | 5.60 | (2.68-11.7) | <.001 |
M6, 6 months from transplant; M12, 12 months from transplant.